| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1033654891 |
| P356 | DOI | 10.1007/S00221-013-3621-2 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1007/s00221-013-3621-2 |
| P698 | PubMed publication ID | 23811734 |
| P2093 | author name string | Susan H Fox | |
| Philippe Huot | |||
| P2860 | cites work | L-DOPA: From a biologically inactive amino acid to a successful therapeutic agent | Q22252689 |
| The history of dopamine and levodopa in the treatment of Parkinson's disease | Q22252881 | ||
| A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model | Q24646533 | ||
| Staging of brain pathology related to sporadic Parkinson's disease | Q28131702 | ||
| A review of central 5-HT receptors and their function | Q28142963 | ||
| EVIDENCE FOR THE EXISTENCE OF MONOAMINE-CONTAINING NEURONS IN THE CENTRAL NERVOUS SYSTEM. I. DEMONSTRATION OF MONOAMINES IN THE CELL BODIES OF BRAIN STEM NEURONS | Q28201187 | ||
| Serotonin receptors | Q28279882 | ||
| Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist | Q28296508 | ||
| Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system | Q28303834 | ||
| Cyproheptadine in levodopa-induced dyskinesia in parkinsonism | Q28331450 | ||
| Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias | Q28373162 | ||
| Quetiapine for l-dopa-induced psychosis in PD | Q28375503 | ||
| Stages in the development of Parkinson's disease-related pathology | Q29615834 | ||
| A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. | Q30419918 | ||
| Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction | Q30465807 | ||
| Mirtazapine in Parkinsonian tremor | Q44243188 | ||
| Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease. | Q44291662 | ||
| Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study | Q44324829 | ||
| [[123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy | Q44325032 | ||
| Radioreceptor binding profile of the atypical antipsychotic olanzapine. | Q49130929 | ||
| Monoamines in the human neostriatum: Topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor | Q51116310 | ||
| Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. | Q52002538 | ||
| Serotonergic dysfunction in depression associated with Parkinson's disease | Q52041948 | ||
| Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life. | Q53247825 | ||
| Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. | Q53439907 | ||
| MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation. | Q53593907 | ||
| Sertraline for the treatment of depression in Parkinson's disease. | Q53964557 | ||
| Open pilot trial of ritanserin in parkinsonism. | Q54150447 | ||
| The Serotonin Syndrome | Q55871784 | ||
| Movement Disorders Associated With the Serotonin Selective Reuptake Inhibitors | Q55893215 | ||
| SPECT imaging of dopamine and serotonin transporters with [123I]?-CIT. Binding kinetics in the human brain | Q56287502 | ||
| Tolerability of paroxetine in Parkinson's disease: A prospective study | Q57203470 | ||
| Quetiapine as an Alternative to Clozapine in the Treatment of Dopamimetic Psychosis in Patients with Parkinson's Disease | Q58243485 | ||
| Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease | Q63498496 | ||
| Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease | Q64764458 | ||
| Paroxetine in Parkinson's disease: effects on motor and depressive symptoms | Q64765320 | ||
| Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease. | Q64855163 | ||
| Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group | Q64860574 | ||
| A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group | Q64955097 | ||
| Clozapine in the treatment of psychosis in Parkinson's disease | Q69707099 | ||
| L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study | Q70958058 | ||
| Aromatic L-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence study | Q71292888 | ||
| D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients | Q71776312 | ||
| Does fluoxetine aggravate Parkinson's disease? A pilot prospective study | Q72000199 | ||
| Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase | Q72111871 | ||
| Organization of ascending serotonin systems in the adult rat brain. A radioautographic study after intraventricular administration of [3h]5-hydroxytryptamine | Q72632358 | ||
| Worsening of Parkinson's disease by citalopram | Q73503039 | ||
| Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease | Q79169769 | ||
| Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis | Q79345127 | ||
| Aripiprazole associated with severe exacerbation of Parkinson's disease | Q79830507 | ||
| In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability | Q80229338 | ||
| Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease | Q82531361 | ||
| Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias | Q83892600 | ||
| Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque | Q95823022 | ||
| Effects of quetiapine at low doses on psychosis motor disability and stress of the caregiver in patients with Parkinson's disease | Q44364467 | ||
| Long‐term outcome of quetiapine use for psychosis among parkinsonian patients | Q44423672 | ||
| Akathisia as a side effect of antipsychotic treatment with quetiapine in a patient with Parkinson's disease | Q44464254 | ||
| SSRIs in the treatment of depression in Parkinson's disease | Q44467578 | ||
| Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT. | Q44468997 | ||
| Mirtazapine in L-dopa-induced dyskinesias | Q44536093 | ||
| Effect of ritanserin, a highly selective 5-HT2 receptor antagonist, on Parkinson's disease | Q44592095 | ||
| Quetiapine as treatment for dopaminergic‐induced dyskinesias in Parkinson's disease | Q44611400 | ||
| Buspirone in Parkinson's disease | Q44715025 | ||
| Aripiprazole and Parkinson's disease psychosis | Q44750302 | ||
| Ziprasidone in Parkinson's disease psychosis | Q44756176 | ||
| Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience | Q44848477 | ||
| Does fluoxetine exacerbate Parkinson's disease? | Q44872549 | ||
| Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). | Q44977032 | ||
| Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years | Q45155172 | ||
| The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa | Q45711592 | ||
| Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study. | Q45966206 | ||
| Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats. | Q46153193 | ||
| Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia | Q46294946 | ||
| Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson's disease dementia | Q46326992 | ||
| Quantitative autoradiography of 5-HT4 receptors in brains of three species using two structurally distinct radioligands, [3H]GR113808 and [3H]BIMU-1. | Q46708242 | ||
| Aripiprazole in psychosis associated with Parkinson's disease | Q46716936 | ||
| The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. | Q46834396 | ||
| Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease | Q46935041 | ||
| Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. | Q48095855 | ||
| Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter | Q48121057 | ||
| The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy | Q48144715 | ||
| The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. | Q48144769 | ||
| Decrease of serotonin-S2 receptors in temporal cortex of patients with Parkinson's disease and progressive supranuclear palsy | Q48147669 | ||
| Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats | Q48192232 | ||
| Aminergic systems in Alzheimer's disease and Parkinson's disease | Q48225859 | ||
| Biochemical pathophysiology of Parkinson's disease. | Q48258284 | ||
| Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model | Q48270157 | ||
| Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram | Q48276587 | ||
| Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex. | Q48294523 | ||
| Parkinson's disease: decreased density of 3H-imipramine and 3H-paroxetine binding sites in putamen. | Q48363578 | ||
| Buspirone, Parkinson's disease, and the locus ceruleus. | Q48421445 | ||
| Depressive illness in Parkinson's disease--indication of a more advanced and widespread neurodegenerative process? | Q48443502 | ||
| The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture. | Q48543386 | ||
| Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease. | Q48614497 | ||
| Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases. | Q48630985 | ||
| The neuropathologic basis of different clinical subgroups of Parkinson's disease. | Q48633612 | ||
| Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. | Q48737270 | ||
| Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. | Q48798374 | ||
| Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease. | Q48846598 | ||
| Pathological basis for neurotransmitter changes in Parkinson's disease | Q48857336 | ||
| Clozapine prevents recurrence of psychosis in Parkinson's disease | Q48893510 | ||
| Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. | Q48935333 | ||
| Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. | Q49046932 | ||
| Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. | Q49095990 | ||
| Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms | Q30466047 | ||
| Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. | Q30495446 | ||
| Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. | Q30783824 | ||
| Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. | Q31039577 | ||
| [123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients | Q32052220 | ||
| Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration | Q33387798 | ||
| Destruction of dopaminergic neurons in the midbrain by 6-hydroxydopamine decreases hippocampal cell proliferation in rats: reversal by fluoxetine | Q33533358 | ||
| The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease | Q33607256 | ||
| Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease | Q33884378 | ||
| Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds | Q33929303 | ||
| Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models | Q33956111 | ||
| The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor | Q33959664 | ||
| Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist | Q33989753 | ||
| Movement disorders associated with the serotonin selective reuptake inhibitors | Q34063636 | ||
| Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time. | Q34184343 | ||
| 3,4-Methylenedioxymethamphetamine (Ecstasy) Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates | Q34268490 | ||
| Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease | Q34272602 | ||
| Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors | Q34316202 | ||
| Dopamine depletion impairs precursor cell proliferation in Parkinson disease. | Q34326801 | ||
| Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system | Q34395267 | ||
| Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. | Q34406533 | ||
| The emerging role of clozapine in the treatment of movement disorders | Q34434857 | ||
| Brain serotonin transporter binding in non-depressed patients with Parkinson's disease | Q34619565 | ||
| Spared caudal brainstem SERT binding in early Parkinson's disease | Q34724279 | ||
| The neuropathological basis for depression in Parkinson's disease | Q34764454 | ||
| Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB. | Q34801837 | ||
| The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia | Q34811957 | ||
| Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys | Q34938279 | ||
| Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats | Q35000569 | ||
| Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia | Q35038040 | ||
| Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation | Q35087525 | ||
| Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study | Q35479427 | ||
| Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up | Q35572611 | ||
| ??? | Q64865570 | ||
| Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model | Q35654251 | ||
| Antidepressant treatment of veterans with Parkinson's disease and depression: analysis of a national sample | Q36026290 | ||
| Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats | Q36243814 | ||
| ACP-103, a 5-HT2A receptor inverse agonist | Q36547468 | ||
| Loss of thalamic serotonin transporters in early drug-naïve Parkinson's disease patients is associated with tremor: an [(123)I]beta-CIT SPECT study. | Q36738260 | ||
| Buspirone in the treatment of levodopa induced dyskinesias | Q36946985 | ||
| Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. | Q37103028 | ||
| Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats | Q37162053 | ||
| Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias | Q37260948 | ||
| The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats | Q37341623 | ||
| Current use of clozapine in Parkinson disease and related disorders | Q37659762 | ||
| Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism? | Q37904514 | ||
| The serotonergic system in Parkinson's disease | Q37924025 | ||
| Effects of the antidepressant fluoxetine on the subcellular localization of 5-HT1A receptors and SERT. | Q38028902 | ||
| The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model | Q39289498 | ||
| Parkinson's disease: Distribution of Lewy bodies and monoamine neuron system | Q39992564 | ||
| Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial | Q40271567 | ||
| Dopamine uptake in serotoninergic terminals in vitro: A valuable tool for the histochemical differentiation of catecholaminergic and serotoninergic terminals in rat cerebral structures | Q40897516 | ||
| In vitro uptake of dopamine in serotoninergic nerve terminals: a fluorescence histochemical study on vibratome sections of the rat cerebral cortex | Q40940848 | ||
| Retrospective study of selegiline-antidepressant drug interactions and a review of the literature | Q41485192 | ||
| Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine | Q42058566 | ||
| Levodopa-induced dyskinesias are improved by fluoxetine | Q42274453 | ||
| Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. A high potency effect of clozapine | Q42279439 | ||
| Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. | Q42284617 | ||
| Buspirone in levodopa-induced dyskinesias | Q42285208 | ||
| Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. | Q42477740 | ||
| Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey | Q42481728 | ||
| Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. | Q42557906 | ||
| Exacerbation of parkinsonism caused by fluoxetine | Q42562961 | ||
| Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition | Q42636297 | ||
| Positive association between striatal serotonin level and abnormal involuntary movements in chronic L-DOPA-treated hemiparkinsonian rats | Q42777274 | ||
| Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures | Q42794711 | ||
| Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. | Q42872557 | ||
| Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats. | Q42880723 | ||
| Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations | Q42970955 | ||
| Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study | Q42994792 | ||
| Serotonin 2A receptors and visual hallucinations in Parkinson disease | Q43102377 | ||
| Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease. | Q43156735 | ||
| L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia | Q43202012 | ||
| In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease | Q43670960 | ||
| 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA. | Q43675942 | ||
| A clinical study of methysergide in parkinsonism: Evidence against a serotonergic mechanism | Q43748604 | ||
| Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease | Q43847894 | ||
| Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease | Q43914500 | ||
| Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models | Q44214535 | ||
| P433 | issue | 4 | |
| P1104 | number of pages | 14 | |
| P304 | page(s) | 463-476 | |
| P577 | publication date | 2013-06-28 | |
| P1433 | published in | Experimental Brain Research | Q13358841 |
| P1476 | title | The serotonergic system in motor and non-motor manifestations of Parkinson's disease | |
| P478 | volume | 230 |
| Q38793660 | Chemical anatomy of pallidal afferents in primates. |
| Q28397369 | Commentary: Evaluation of Models of Parkinson's Disease |
| Q34382560 | Depression and Parkinson's disease: current knowledge |
| Q36154790 | Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease |
| Q53070835 | Effects of the Serotonin 5-HT1A Receptor Biased Agonists, F13714 and F15599, on Striatal Neurotransmitter Levels Following L-DOPA Administration in Hemi-Parkinsonian Rats. |
| Q53410082 | Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity. |
| Q89533763 | High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinson's disease cohort |
| Q34443504 | Managing depression in Parkinson's patients: risk factors and clinical pearls |
| Q47289908 | Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias |
| Q51583546 | Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors. |
| Q35829940 | Metabolomics Approach Reveals Integrated Metabolic Network Associated with Serotonin Deficiency |
| Q35165280 | Monoamine reuptake inhibitors in Parkinson's disease |
| Q35699789 | Nonmotor Symptoms and Subthalamic Deep Brain Stimulation in Parkinson's Disease |
| Q48492369 | Parkinson's disease psychosis as a serotonin-dopamine imbalance syndrome. |
| Q51781286 | Parkinson's disease psychosis: presentation, diagnosis and management. |
| Q50092339 | Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis. |
| Q21129423 | Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications |
| Q35595426 | Recent progress of imaging agents for Parkinson's disease |
| Q38378640 | Selective dysfunction of basal ganglia subterritories: From movement to behavioral disorders |
| Q48345542 | Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias. |
| Q30795299 | Severely impaired hippocampal neurogenesis associates with an early serotonergic deficit in a BAC α-synuclein transgenic rat model of Parkinson's disease |
| Q35783515 | Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease |
| Q48140796 | Transcranial midbrain sonography and depressive symptoms in patients with Parkinson's disease |
Search more.